A P2b clinical trial of Tcelna Read more…
A key step in bringing this vector to the clinic was to demonstrate that it is both safe and feasible to transfect the vector into human stem cells and for the RNA molecules to persist in the immune cells of the patient. Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.